Not All Milligrams Are Equal: A Canadian Patient's Guide to Verifying Dosage When Switching Between Medication Brands

When a Simple Switch Becomes a Complex Problem

For most Canadians, receiving a generic version of a familiar medication feels routine — perhaps even reassuring, given the cost savings involved. Yet beneath the surface of what appears to be an administrative substitution lies a landscape of clinical nuance that catches patients and, occasionally, even prescribers off guard.

Dosage equivalency is not always as straightforward as it seems. A medication dispensed in one strength under a brand name may behave differently from a generic carrying the same numerical dose, particularly when formulation type, salt form, or release mechanism differs. Understanding where these discrepancies arise — and knowing how to catch them before they cause harm — is one of the most valuable skills a Canadian patient can develop.

Where the Numbers Can Mislead You

Consider the case of a patient in Ontario who had been stabilised on an extended-release formulation of a commonly prescribed cardiovascular medication. When her prescription was switched to a generic during a routine refill, the dispensed product was an immediate-release version at the same stated milligram strength. Because the release profile differed significantly, her blood concentration levels fluctuated throughout the day rather than remaining steady, and within two weeks she was experiencing symptoms her physician initially attributed to a new condition entirely.

This scenario is not hypothetical. Extended-release, controlled-release, and sustained-release formulations are not interchangeable with their immediate-release counterparts, even when the printed dose appears identical. The same principle applies to medications with different salt forms — levothyroxine sodium and levothyroxine are chemically related but not clinically equivalent at the same stated dose, a distinction that carries particular weight for patients managing thyroid conditions.

A British Columbia pharmacist working in a community setting described a similarly instructive case involving a patient transitioning between two versions of an antiepileptic drug. The branded product and the generic shared an identical milligram count on the label, yet the bioavailability differed enough to push the patient toward a subtherapeutic range. The prescribing neurologist had not been notified of the switch, and the pharmacist caught the issue only because the patient mentioned feeling "off" during a routine pickup.

Why Canadian Regulations Permit Substitution — and Where the Gaps Lie

Health Canada requires that generic medications demonstrate bioequivalence to their reference brand, meaning that the rate and extent of drug absorption must fall within an acceptable statistical range. In the vast majority of cases, this standard is sufficient to ensure clinical equivalence. However, for medications with narrow therapeutic indices — drugs where even modest fluctuations in blood concentration can tip a patient from therapeutic to toxic or subtherapeutic — the permissible range of variation becomes clinically meaningful.

Thyroid hormones, anticoagulants, antiepileptics, immunosuppressants, and certain cardiac medications fall into this high-sensitivity category. Canadian pharmacists are generally trained to flag substitutions involving these drug classes, but the system depends on the pharmacist having complete information — including whether a patient has previously been stabilised on a specific brand, and whether the prescribing physician has indicated that substitution is appropriate.

Patients who use multiple pharmacies, receive medications through mail-order services, or move between provinces face a heightened risk of information gaps. When a patient's history is not fully visible to the dispensing pharmacist, the safeguard that the professional relationship provides is necessarily limited.

The Role of Formulation in Dosage Equivalency

Beyond narrow therapeutic index medications, formulation differences affect a broader range of drug classes than many patients realise. Topical preparations, for instance, may carry the same active ingredient concentration but differ in their vehicle — the base cream, gel, or ointment — which influences how deeply the active compound penetrates tissue. A dermatologist in Alberta noted that patients switching between branded and generic topical corticosteroids sometimes report reduced efficacy not because the active ingredient is deficient but because the vehicle formulation affects absorption in a clinically perceptible way.

Similarly, oral medications that dissolve in the mouth, medications delivered via transdermal patch, and inhalers for respiratory conditions each carry formulation-specific considerations. Metered-dose inhalers, for example, may deliver slightly different particle sizes depending on the manufacturer, influencing how deeply the medication penetrates the airways. For patients managing asthma or chronic obstructive pulmonary disease, this distinction is not trivial.

Practical Verification Steps Before You Leave the Pharmacy

The most effective safeguard against dosage conversion errors is a habit of active verification at the point of dispensing. Canadian patients can adopt the following steps regardless of whether they are collecting a prescription in person or receiving a mail-order delivery:

Confirm the formulation type explicitly. Ask the pharmacist whether the dispensed product is immediate-release, extended-release, or another formulation, and verify that this matches what you were previously taking. Do not assume that the same milligram strength implies the same release profile.

Check the drug name and salt form. If your previous prescription listed a specific salt form — for example, metoprolol tartrate versus metoprolol succinate — confirm that the new product matches. These are not interchangeable despite sharing the same base compound name.

Request a side-by-side comparison. Most pharmacists can retrieve the product information for both your previous and current medication. Asking to review these together takes only a few minutes and can surface discrepancies before they become clinical problems.

Notify your prescribing physician of every substitution. Your pharmacist and physician do not always communicate automatically about brand changes. A brief message through your patient portal or a call to the clinic ensures that your physician is aware of what you are actually taking and can adjust monitoring or dosing instructions accordingly.

Inspect mail-order deliveries carefully. If you receive medications through a licensed online pharmacy, compare the dispensed product against your previous supply before disposing of the old packaging. Differences in tablet appearance, coating, or labelling may indicate a formulation change worth confirming with the dispensing pharmacist.

Keep a personal medication record. Documenting not just the drug name and dose but the specific brand or manufacturer, formulation type, and any clinical response notes gives both you and your healthcare team a reference point when future switches occur.

A Checklist for High-Risk Transitions

For patients managing conditions where dosage precision is especially critical, the following checklist provides a structured approach to any medication transition:

• Confirm the formulation type matches your previous prescription
• Verify the salt form if applicable
• Check that the manufacturer's listed bioavailability is consistent with your previous product
• Inform your prescribing physician of the switch in writing
• Schedule a follow-up appointment or blood test if your medication falls into a narrow therapeutic index category
• Report any new or returning symptoms to your pharmacist or physician within the first two weeks
• Update your personal medication record with the new product details

The Pharmacist as Your First Line of Verification

Canadian pharmacists are among the most accessible healthcare professionals in the country, and their expertise extends well beyond counting tablets. When a dosage conversion question arises — whether at a community pharmacy counter or through the consultation service of a licensed online pharmacy — the pharmacist is positioned to identify discrepancies that a patient acting alone might miss entirely.

At CanadianPharmGRx, every prescription dispensed is reviewed by a licensed Canadian pharmacist before it reaches the patient. That review process includes confirmation of formulation type, dosage accuracy, and appropriateness relative to the patient's profile. For patients navigating a brand or generic transition, this layer of professional oversight is not incidental — it is fundamental to safe pharmaceutical care.

The milligrams printed on a label tell only part of the story. Understanding the rest of it is a responsibility that patients, pharmacists, and physicians share equally.